Revolution and Allogene’s equity financings are a microcosm of biotech’s historic struggle.
ApexOnco Front Page
Recent articles
Lilly buys the dual-payload ADC specialist before it’s dosed a single patient.
The industry’s first ALK degrader starts its first human study.
AbbVie’s PD-1 x VEGF agreement with RemeGen was the first-quarter’s biggest.
The latest Chinese pivotal study of iza-bren will be in first-line small-cell lung cancer.
A $3.15bn deal follows a December 2024 option agreement.
The groups spend big on Terns and Arcellx.
Rinzimetostat efficacy wanes further as the company moves into phase 3.
